Document Detail

Determination of MUC1 in Sera of Ovarian Cancer Patients and in Sera of Patients with Benign Changes of the Ovaries with CA15-3, CA27.29, and PankoMab.
MedLine Citation:
PMID:  22593508     Owner:  NLM     Status:  In-Data-Review    
MATERIALS AND METHODS: Sera of 123 patients diagnosed with benign or malignant changes of the ovaries were obtained before surgery. CA15-3 was analysed with an automated ELISA system (Immulite 2000). CA27.29 was measured with the ST AIA-PACK CA27.29 for the AIA-600II-Analyzer (Tosoh Bioscience, Belgium). The release of MUC1 fragments carrying the TA-MUC1 epitope was analysed with an ELISA using the PankoMab antibody.
RESULTS: Using the already established markers CA15-3 and CA27.29, significant differences between benign and malignant changes of the ovaries were found. The same result was obtained with the newly developed TA-MUC1 test. In contrast to CA15-3 and CA27.29, however, the median of TA-MUC1 was lower in sera from patients with ovarian cancer compared to sera from patients with benign diseases of the ovary. However, sera of patients with benign ovarian diseases had significantly higher TA-MUC1 values compared to sera of healthy individuals. The risk score of TA-MUC1 achieved an area under the curve (AUC) of 78.4% in receiver operating characteristic (ROC) curves and a sensitivity of 37% for the prediction of ovarian disease, at 95% specificity.
CONCLUSION: In this study we employed an additional marker for MUC1 which recognizes a more tumour-specific MUC1 epitope (TA-MUC1). We obtained results showing significant differences between detection in benign and malignant ovarian diseases. Although the mean MUC1 values were elevated in sera of patients with ovarian cancer compared to values of patients with benign cysts, by using all three test systems, a different result was found by analysing the median TA-MUC1 values. PankoMab could be a useful, additional tool for obtaining conclusive information on the transformation process from benign to malignant state in ovarian tissues.
Udo Jeschke; Irmi Wiest; Anamur Lan Schumacher; Markus Kupka; Brigitte Rack; Renate Stahn; Uwe Karsten; Doris Mayr; Klaus Friese; Darius Dian
Related Documents :
19282758 - Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognos...
14687748 - How long should patients be followed after molar pregnancy? analysis of serum hcg follo...
8961698 - Serum alpha 1 antitrypsin and pulmonary emphysema.
6117168 - Hcg and hcg subunits as tumour markers in patients with endocrine pancreatic tumours an...
9385348 - The relationship between fibromyalgia and the multiple chemical sensitivity syndrome.
24669818 - Asymmetric dimethylarginine levels in patients with cutaneous anthrax: a laboratory ana...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2185-9     Citation Subset:  IM    
Department of Obstetrics and Gynaecology, Ludwig Maximilians University of Munich, Maistrasse 11, D-80337 Munich, Germany
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nature and Dynamics of Nucleosome Release from Neoplastic and Non-neoplastic Cells.
Next Document:  Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under spe...